# An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol

> **NCT01739764** · PHASE4 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 215 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** Vemurafenib

## Key facts

- **NCT ID:** NCT01739764
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02-19
- **Primary completion:** 2020-02-17
- **Final completion:** 2020-02-17
- **Target enrollment:** 215 (ACTUAL)
- **Last updated:** 2021-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01739764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01739764, "An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01739764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*